Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332341 · ClinicalTrials.gov registry record · Early Phase 1
Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
A Early Phase 1 study of Allogeneic Hematopoietic Cell Transplantation, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04332341 is a Early Phase 1 study of Allogeneic Hematopoietic Cell Transplantation that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04332341, a Early Phase 1 study of Allogeneic Hematopoietic Cell Transplantation, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.
Conditions Studied
Interventions
- DRUG Nicotinamide riboside (NR)
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-05-19 |
| Est. Completion | 2026-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04332341
The ClinicalTrials.gov registry entry for NCT04332341 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Hematopoietic Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide riboside (NR) is the first listed.
NCT04332341 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04332341 about?
NCT04332341 is a clinical study titled "Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation". The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinami...
What is the current status of trial NCT04332341?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-05-19. Estimated completion is 2026-09.
What conditions does trial NCT04332341 study?
This clinical trial studies the following conditions: Allogeneic Hematopoietic Cell Transplantation.
What interventions are being tested in trial NCT04332341?
The interventions under investigation include: Nicotinamide riboside (NR) (DRUG).
Who is sponsoring clinical trial NCT04332341?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04332341 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Hematopoietic Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.